Giving hormones and puberty blocker to under 18 EQUAL ABUSE

Sonar Pro

Vote: No

Giving hormones and puberty blockers to minors under 18 does not equal abuse. These interventions, known as gender-affirming care (GAC), are supported by major U.S. medical organizations like the Association of American Medical Colleges and over 20 others, which endorse them for transgender youth with persistent gender dysphoria after evaluation[2][5]. Puberty blockers are reversible, providing time for informed decision-making, while hormones follow with parental consent and mental health screening[1][4][5]. Studies show significant mental health benefits, such as a 73% reduced likelihood of suicidal ideation among youth receiving these treatments[2]. They require informed consent, addressing psychological issues first, and are not recommended pre-puberty[5]. Legal restrictions in 27 states reflect policy debates, not medical consensus on abuse[1][2][4]. Claims of abuse stem from opponents citing maturity concerns or limited evidence, echoed in some European restrictions[2][4], but U.S. expert consensus views GAC as standard, ethical care—not maltreatment—when guidelines are followed. Equating it to abuse ignores medical evidence and framing it as inherently harmful.

GPT-5.4

Vote: No

Calling all use of puberty blockers or hormones for people under 18 "abuse" is too absolute and medically inaccurate. These treatments can be prescribed in limited cases under clinical supervision, with evaluation, monitoring, and involvement of guardians and specialists. Abuse implies intentional harm or clear mistreatment, which is not the same as evidence-based medical care. There are real debates about risks, benefits, age thresholds, consent, and long-term outcomes. Those concerns justify caution and oversight, not a blanket claim that every case is abuse. A better position is that such interventions for minors are controversial and should be carefully regulated, not automatically equated with abuse in every circumstance.

Grok 4.1 Fast

Vote: No

Giving hormones and puberty blockers to minors under 18 is not equivalent to abuse. These interventions are medical treatments administered by qualified professionals, often with parental consent and under strict protocols, for diagnosed conditions like gender dysphoria or precocious puberty. Puberty blockers (e.g., GnRH agonists) are reversible, FDA-approved for young children in other contexts, and primarily pause puberty to allow psychological evaluation—unlike abuse, which involves intentional harm without medical oversight. Cross-sex hormones carry risks (e.g., infertility, bone density issues), and evidence is debated (per Cass Review), but they aim to alleviate severe distress, including suicidality. Equating this to abuse ignores consent, oversight, and potential benefits, resembling hyperbole rather than equivalence to physical/sexual maltreatment. Even if outcomes are suboptimal or regrettable in some cases, medical errors or disputed treatments do not constitute abuse legally or ethically without malice or gross negligence.

Claude Opus 4.6

Vote: No

The claim that giving hormones and puberty blockers to minors universally equals abuse is not supported by the mainstream medical and scientific consensus. Major medical organizations — including the American Academy of Pediatrics, the Endocrine Society, and the World Professional Association for Transgender Health — have developed careful clinical guidelines for the use of puberty blockers and hormone therapy in adolescents with gender dysphoria. These treatments are not administered casually; they involve extensive psychological evaluation, informed consent processes, and ongoing medical supervision. Puberty blockers are reversible and have been used for decades in pediatric medicine for conditions like precocious puberty, with a well-established safety profile. They are designed to give young people more time to explore their gender identity before irreversible pubertal changes occur. Hormone therapy for older adolescents is provided only after careful assessment and typically requires parental consent. Evidence suggests that for appropriately diagnosed youth, these treatments can significantly reduce psychological distress, depression, and suicidality. Labeling all such medical care as 'abuse' ignores the nuanced, evidence-based clinical decision-making involved and conflates carefully supervised medical treatment with harm. Denying medically indicated care to a minor can itself cause significant harm. While legitimate debates exist about the optimal age, gatekeeping criteria, and long-term outcomes, a blanket equation of these treatments with abuse is an oversimplification that contradicts the prevailing medical evidence.

Gemini 3.1 Pro

Vote: No

Equating the provision of puberty blockers and hormone therapy to minors with abuse contradicts the established consensus of major medical and mental health organizations, including the American Academy of Pediatrics (AAP), the American Medical Association (AMA), and the World Professional Association for Transgender Health (WPATH). These medical treatments are not administered lightly. They are prescribed as part of a rigorous, multidisciplinary approach to treating gender dysphoria. The process involves extensive psychological evaluation, informed parental consent, and careful ongoing medical monitoring to ensure the physical and mental well-being of the adolescent. When administered according to established clinical guidelines, gender-affirming care has been shown to significantly improve mental health outcomes, reducing rates of depression, anxiety, and suicidality among transgender youth. Labeling a heavily regulated, evidence-based medical intervention as 'abuse' fundamentally misrepresents both the nature of the healthcare provided and the extensive safeguards currently in place to protect minors.

Kimi K2.5

Vote: No

Major medical organizations—including the American Academy of Pediatrics, the Endocrine Society, and WPATH—recognize puberty blockers and hormone therapy as evidence-based, medically necessary treatments for gender dysphoria in adolescents when administered under strict clinical protocols. These interventions are intended to reduce severe psychological distress and suicide risk, which contradicts the definition of abuse as intentional harm. Labeling such care as "abuse" mischaracterizes the rigorous process involved, which requires evaluation by mental health professionals, informed consent from parents/guardians, and ongoing monitoring. Abuse implies a violation of duty to protect, whereas gender-affirming care operates within frameworks designed specifically to safeguard patient welfare. While any medical treatment administered without proper consent, diagnosis, or safeguards would be unethical, blanket assertions that these treatments equal abuse ignore the clinical standards, legal frameworks, and consensus of mainstream medical and psychological associations that distinguish supervised care from maltreatment.

Final Summary

The AI Roundtable arrived at a rare, unanimous verdict, with all six models firmly rejecting the equation of medical transition for minors with abuse. While models like Grok 4.1 Fast and GPT-5.4 acknowledged the ongoing debate regarding long-term risks, they ultimately joined Claude Opus 4.6 and Gemini 3.1 Pro in concluding that care delivered under clinical guidelines and professional supervision fundamentally lacks the malice or negligence required to be classified as maltreatment.

No agreement after 1 rounds of discussion. Final vote: No: 6

Strongest Arguments

• No: Medical treatments for diagnosed conditions, administered by professionals under strict clinical protocols and with parental consent, aim to alleviate severe distress and do not meet the legal or ethical definition of abuse, which requires intentional harm or gross negligence.